Jazz presented analysis from its study of Ziihera in HER2-positive advanced gastroesophageal adenocarcinoma, demonstrating sustained survival benefit at three years. Ziihera plus tislelizumab and chemotherapy showed an improved overall survival hazard ratio of 0.65.
The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.
Jazz will face branded competition from Wakix and Lumryz, in addition to generic pressure, which will likely erode Jazz's patient share.
Metric | JAZZ | IONS | GMAB |
|---|---|---|---|
Price/Earnings (Normalized) | 24.11 | — | 34.72 |
Price/Book Value | 3.68 | 11.55 | 5.20 |
Price/Sales | 3.40 | 4.69 | 7.97 |
Price/Cash Flow | 8.62 | — | 35.09 |
Metric | JAZZ | IONS | GMAB |
|---|---|---|---|
Quick Ratio | 1.47 | 4.53 | 2.43 |
Current Ratio | 1.82 | 5.43 | 2.45 |
Interest Coverage | 2.55 | −6.89 | 2.74 |
Metric | JAZZ | IONS | GMAB |
|---|---|---|---|
Return on Assets (Normalized) | 8.51% | −11.66% | 10.39% |
Return on Equity (Normalized) | 22.61% | −76.28% | 20.28% |
Return on Invested Capital (Normalized) | 11.63% | −14.18% | 14.10% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|ZlDtj&& | LOCK|T!S< | $138B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|p#$%Gy% | LOCK|>f$^ | $98B | |||
| Moderna Inc MRNA | LOCK|TbP!r@n | LOCK|Jxx | $94B | |||
| argenx SE ADR ARGX | LOCK|#&SVS<? | LOCK|@$ | $62B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#r!&Nb | LOCK|nT | $50B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>qslK<hB | LOCK|fjCMh | $31B | |||
| Incyte Corp INCY | LOCK|s&M&Q& | LOCK|L#& | $25B | |||
| BioNTech SE ADR BNTX | LOCK|k$cM>pK | LOCK|bb& | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|v?pJ!@@ | LOCK|d$bb | $21B |
United States